GlassScriptPhysician profile
Gregory K Fulcher
NPI 1104969252
$4,826.89
in general payments reported to CMS, 2019-2025
47 companies · $985 in 2025
The $985 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $211 · 2021: $15.03 · 2022: $492 · 2023: $936 · 2024: $925 · 2025: $985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,762 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,761.53 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $622.61 | 2019-2025 | |
| Novo Nordisk INC | $342.51 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $340.83 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $332.45 | 2019-2025 | Breztri, Airsupra, Bevespi Aerosphere |
| Astellas Pharma US INC | $308.97 | 2019-2025 | Veozah |
| Pfizer INC. | $246.14 | 2019-2025 | |
| Amgen INC. | $217.67 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $193.81 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $189.56 | 2023-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $169.62 | 2019-2025 | Trintellix |
| Abbott Laboratories | $145.69 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Sanofi-Aventis U.S. LLC | $143.93 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.63 | 2019-2025 | Jardiance, Spevigo |
| Amarin Pharma, INC. | $106.82 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $100.30 | 2022-2025 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Fulcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.